Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9911990 | 0.78 | RAB9A (0.49) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL17494888 | 0.76 | RAB9A (0.44) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL21479586 | 0.75 | RAB9A (0.40) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL17494864 | 0.73 | RAB9A (0.56) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL5030822 | 0.73 | RAB9A (0.42) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL3051505 | 0.72 | RAB9A (0.48) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL3056330 | 0.71 | LMNA (0.54) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL3052229 | 0.71 | RAB9A (0.47) | RAB9ASMN1; SMN2GAANPC1LMNA | |
| SCHEMBL4136703 | 0.70 | KDM4E (0.33) | IDH1 | |
| SCHEMBL6239023 | 0.69 | RAB9A (0.39) | RAB9ASMN1; SMN2GAANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| EP-4373814-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117651699-A | Compounds and compositions for the treatment of coronavirus related diseases | 诺华股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| WO-2023002409-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092016-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CORONAVIRAL RELATED DISEASES | ACE2, ACE, TMPRSS2 | RAB9A 2561/4885SMN1; SMN2 3396/4885GAA 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.